Monopar Therapeutics price target raised to $95 from $76 at Piper Sandler

Piper Sandler analyst Biren Amin raised the firm’s price target on Monopar Therapeutics (MNPR) to $95 from $76 and keeps an Overweight rating on the shares. The firm notes the company highlighted a new analysis of the Phase 2 ALXN1840-WD-204 study that disputes the earlier conclusion regarding ALXN1840’s lack of effect on copper excretion in patients with Wilson Disease. By considering all pathways of copper loss, beyond just fecal and urinary excretion, this analysis demonstrates that ALXN1840 effectively promotes copper excretion. Herein, Piper also compares and contrasts the recent accelerated approval of Stealth Bio’s elamipretide in Barth syndrome, as it sees several parallels that bode well for ALXN1840’s potential approval with NDA filing expected in Q1 2026.